Serum C-tau Precition of Brain Damage in Mild TBI
Serum C-tau Precition of Brain Damage in Mild TBI
批准号:
6689352
负责人:
FRANK P ZEMLAN
金额:
$12.86万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-01 至 2004-12-31
中文摘要
描述(申请人提供):目前第一阶段可行性研究的目标是开发一种基于血清的定量生物标记物,用于检测轻度创伤性脑损伤(TBI)的神经元损伤。脑震荡后综合征(PCS)被认为是轻度颅脑损伤患者残疾的主要原因。虽然大约40%的轻度颅脑损伤患者会发生PCS,但放射学技术几乎没有发现这些患者。这项研究的目的是开发一种新的神经元损伤的血清生物标志物,用于识别随后发展为PCS的轻度脑损伤患者。我们已经开发了一种夹心ELISA法,它可以定量检测神经元定位的蛋白MAP-tau,它被蛋白水解性切割,并在脑损伤后从受损神经元中释放出来(C-tau)。在初步研究中,我们发现轻度脑外伤患者血清C-tau水平显着升高。这项拟议的研究将确定最初的血清C-tau水平是否可以预测哪些轻度脑外伤患者随后会发展为PCS。我们的具体目标是:具体目标1:确定初始C-tau水平是否是轻度脑外伤患者脑震荡后综合征的可靠预测因子(N=80)。最初的血清C-tau水平(伤后12小时)、头部CT(伤后12小时)和临床实验室数据收集自轻度脑外伤患者(ICD-9850-854;GCS>;12)。PCS的诊断是在3个月的随访中做出的。患者将因存在或不存在PCS而被一分为二。预测PCS的血清C-tau临界值将通过ROC分析确定,并确定初始C-tau水平预测PCS的敏感性、特异性和预测值。具体目标2:确定初始C-tau水平是否可预测轻度脑外伤患者的颅内损伤。特殊目的相似分析1例,但因CT异常存在或不存在而分为两组。具体目标3:确定初始C-tau水平是否是无CT异常的轻度颅脑损伤患者脑震荡后综合征的可靠预测因子。与特定目的1的分析类似,但仅限于无CT异常的患者,预计约占所有患者的85%至90%(N=约70)。
英文摘要
DESCRIPTION (provided by applicant): The objective of the present Phase 1 feasibility study is to develop a quantitative serum-based biomarker for detecting neuronal damage in mild traumatic brain injury (TBI). Postconcussion Syndrome (PCS) is believed to be the cause for much if not all of the disability suffered by mild TBI patients. Although PCS occurs in about 40% of mild TBI patients, radiologic techniques detect few of these patients. The purpose of the proposed studies is to develop a new serum biomarker of neuronal damage for identifying mild TBI patients who subsequently develop PCS. We have developed a sandwich ELISA that quantifies a neuronally localized protein, MAP-tau, that is proteolytically cleaved and released from damaged neurons after brain injury (C-tau). In preliminary studies we demonstrate that serum C-tau levels are significantly elevated in mild TBI patients. The proposed studies will determine if initial serum C-tau levels predict which mild TBI patients subsequently develop PCS. Our Specific Aims are: Specific Aim 1: Determine if initial C-tau levels are a reliable predictor of Postconcussion Syndrome in mild TBI patients (N=80). Initial serum C-tau levels (<12 hrs postinjury), head CT (<12 hrs postinjury) and clinical-laboratory data are collected from mild TBI patients (ICD-9 850-854; GCS>12). Diagnosis of PCS is made at 3-month follow-up. Patients will be dichotomized by presence or absence of PCS. The serum C-tau cut-off for predicting PCS will be determined by ROC analysis and the sensitivity, specificity and predictive value of initial C-tau levels for predicting PCS determined. Specific Aim 2: Determine if initial C-tau levels predict intracranial injury in mild TBI patients. Similar analysis of Specific Aim 1 patients but patients dichotomized by presence or absence of CT abnormality. Specific Aim 3: Determine if initial C-tau levels are a reliable predictor of Postconcussion Syndrome in mild TBI patients with no CT abnormality. Similar analysis as for Specific Aim 1 but restricted to patients with no CT abnormality which is projected to be about 85% to 90% of all patients (N = approximately 70).
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.ajem.2007.10.029
发表时间:
2008-09
期刊:
The American journal of emergency medicine
影响因子:
--
作者:
[Ma M, Lindsell CJ, Rosenberry CM, Shaw GJ, Zemlan FP]
通讯作者:
Zemlan FP
COCAINE THERAPEUTIC: PD2005 DOPAMINE TRANSPORT INHIBITOR
-
批准号:6785636
-
项目类别:
-
资助金额:$13.65万
-
财政年份:2004
-
负责人:FRANK P ZEMLAN
-
依托单位:
Biomarker for Subarachnoid Hemorrhage
-
批准号:6483618
-
项目类别:
-
资助金额:$12.81万
-
财政年份:2002
-
负责人:FRANK P ZEMLAN
-
依托单位:
Melatonin Analog for Sleep Disorders
-
批准号:6712083
-
项目类别:
-
资助金额:$46.32万
-
财政年份:2002
-
负责人:FRANK P ZEMLAN
-
依托单位:
Melatonin Analog for Sleep Disorders
-
批准号:6707905
-
项目类别:
-
资助金额:$50.43万
-
财政年份:2002
-
负责人:FRANK P ZEMLAN
-
依托单位:
Biomarker of Neuronal Damage in Traumatic Brain Injury
-
批准号:6598070
-
项目类别:
-
资助金额:$23.69万
-
财政年份:2001
-
负责人:FRANK P ZEMLAN
-
依托单位:
Biomarker of Neuronal Damage in Traumatic Brain Injury
-
批准号:6612652
-
项目类别:
-
资助金额:$25.73万
-
财政年份:2001
-
负责人:FRANK P ZEMLAN
-
依托单位:
Biomarker of Neuronal Damage in Traumatic Brain Injury
-
批准号:6529679
-
项目类别:
-
资助金额:$27.07万
-
财政年份:2001
-
负责人:FRANK P ZEMLAN
-
依托单位:
Biomarker of Neuronal Damage in Traumatic Brain Injury
-
批准号:6650523
-
项目类别:
-
资助金额:$4.08万
-
财政年份:2001
-
负责人:FRANK P ZEMLAN
-
依托单位:
Neurotoxin Discovery Platform - Drugs of Abuse
-
批准号:6743783
-
项目类别:
-
资助金额:$24.31万
-
财政年份:2000
-
负责人:FRANK P ZEMLAN
-
依托单位:
Neurotoxin Discovery Platform - Drugs of Abuse
-
批准号:6626012
-
项目类别:
-
资助金额:$23.6万
-
财政年份:2000
-
负责人:FRANK P ZEMLAN
-
依托单位:
NEUROTOXIN DISCOVERY PLATFORM - DRUGS OF ABUSE
-
批准号:6135366
-
项目类别:
-
资助金额:$10.8万
-
财政年份:2000
-
负责人:FRANK P ZEMLAN
-
依托单位:
Neurotoxin Discovery Platform - Drugs of Abuse
-
批准号:6484021
-
项目类别:
-
资助金额:$26.18万
-
财政年份:2000
-
负责人:FRANK P ZEMLAN
-
依托单位:
SERUM MAP-TAU IN TRAUMATIC BRAIN INJURY
-
批准号:6071321
-
项目类别:
-
资助金额:$10.71万
-
财政年份:2000
-
负责人:FRANK P ZEMLAN
-
依托单位:
HUMAN SERUM BIOMARKER FOR NEUROTOXICITY
-
批准号:6210766
-
项目类别:
-
资助金额:$10.48万
-
财政年份:2000
-
负责人:FRANK P ZEMLAN
-
依托单位:
CSF MAP-2 IN TRAUMATIC BRAIN INJURY
-
批准号:2793074
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1999
-
负责人:FRANK P ZEMLAN
-
依托单位:
CSF AND PLASMA NEUROFILAMENTS IN TRAUMATIC BRAIN INJURY
-
批准号:6015713
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1999
-
负责人:FRANK P ZEMLAN
-
依托单位:
DOPAMINE FUNCTIONAL SUBTYPES OF SCHIZOPHRENIA
-
批准号:3378322
-
项目类别:
-
资助金额:$16.71万
-
财政年份:1986
-
负责人:FRANK P ZEMLAN
-
依托单位:
DOPAMINE FUNCTIONAL SUBTYPES OF SCHIZOPHRENIA
-
批准号:3378320
-
项目类别:
-
资助金额:$15.44万
-
财政年份:1986
-
负责人:FRANK P ZEMLAN
-
依托单位:
DOPAMINE FUNCTIONAL SUBTYPES OF SCHIZOPHRENIA
-
批准号:3378321
-
项目类别:
-
资助金额:$16.47万
-
财政年份:1986
-
负责人:FRANK P ZEMLAN
-
依托单位:
PEPTIDE/MONOAMINE CONTROL OF SPINAL PAIN TRANSMISSION
-
批准号:3398369
-
项目类别:
-
资助金额:$11.69万
-
财政年份:1983
-
负责人:FRANK P ZEMLAN
-
依托单位: